PNC Financial Services Group Inc. Sells 262 Shares of Repligen Co. (NASDAQ:RGEN)

PNC Financial Services Group Inc. lessened its stake in shares of Repligen Co. (NASDAQ:RGEN) by 7.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,480 shares of the biotechnology company’s stock after selling 262 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Repligen were worth $501,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Resources Management Corp CT ADV bought a new stake in shares of Repligen during the third quarter worth $37,000. Quarry LP grew its stake in shares of Repligen by 796.7% during the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after buying an additional 239 shares during the last quarter. UMB Bank n.a. grew its stake in shares of Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after buying an additional 110 shares during the last quarter. Global Retirement Partners LLC grew its stake in shares of Repligen by 54.0% during the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock worth $53,000 after buying an additional 129 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of Repligen by 15.2% during the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock worth $98,000 after buying an additional 90 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

RGEN stock opened at $144.88 on Thursday. The firm has a market cap of $8.12 billion, a price-to-earnings ratio of -284.08, a PEG ratio of 4.54 and a beta of 0.95. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $200.23. The company’s fifty day simple moving average is $156.78 and its 200 day simple moving average is $148.46.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. On average, analysts expect that Repligen Co. will post 1.72 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on RGEN. TD Cowen assumed coverage on shares of Repligen in a research note on Monday, February 10th. They set a “buy” rating and a $200.00 target price on the stock. JPMorgan Chase & Co. lifted their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a report on Friday, February 21st. Canaccord Genuity Group assumed coverage on shares of Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Finally, Canaccord Genuity Group lifted their price target on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Repligen currently has an average rating of “Hold” and an average price target of $178.64.

Insider Activity

In related news, Director Margaret Pax acquired 250 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.